© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Roflumilast Cream Shows Strong Tolerability in Patients with AD Failing Other Topicals: Daily Dose
March 19th 2025
Your daily dose of the clinical news you may have missed.
What We Mean When We Say "Skin of Color" in Dermatology: A Closer Look with Raj Chovatiya, MD, PhD, MSCI
March 19th 2025
Chovatiya, expert clinical dermatologist and researcher, points out that the term "skin of color" comprises a heterogenous set of topics, in an interview at AAD 2025.
Managing Atopic Dermatitis in Special Populations: Expert Insights for Primary Care
March 18th 2025
In an interview at AAD 2025, Katrina Abuabara, MD, stressed the importance of collaboration between primary care physicians and dermatologists.
Antihistamines Are a Poor Option to Treat Eczema in Older Adults: Clinical Pearl
March 18th 2025
Antihistamines for itch caused by disorders like atopic dermatitis pose more problems, like sedation and fall risk, than they provide relief, according to Daniel Butler, MD.
Emergence of Trichophyton Indotineae: A Call for Culture-Driven Antifungal Therapy
March 17th 2025
Elizabeth Swanson, MD, shares how the rise of T.indotineae, a terbinafine-resistant fungal species, has shifted her treatment approach.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
March 17th 2025
Your daily dose of the clinical news you may have missed.
Daniel Butler, MD, a Leader in Geriatric Dermatology, Says Focus on the Overlap in the Etiology of Itch in Older Adults
March 17th 2025
AAD 2025: Tracing the multiple pathways that contribute to chronic itch vs looking for a singular cause helps optimize choice of therapy, Butler says.
Rethinking Shingles in Children: Expert Insights for Primary Care
March 15th 2025
Shingles is increasingly being observed in healthy, immunocompetent children. Elizabeth Swanson, MD, discusses how to recognize and respond.
Measles Resurgence and Vaccine Efficacy: A Conversation with Elizabeth Swanson, MD
March 14th 2025
Dr Swanson discusses the resurgence of measles and emphasizes the safety and efficacy of the measles vaccine.
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
March 14th 2025
Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.